I'm seeing a possible convergence of events that could propel our PPS much higher....I'm always hoping that during one of these Investor Conference Dog & Pony shows that something big might be announced....but the missing ingredient has always been shares for sale as I see it.  

I've seen something like this before.  

Back in 2015 JP Morgan was the lead on a share offering done by Ziopharm, 10 million shares priced at $8.75 that raised that CAR-T entrant $87.5 million less fees.  That share offering was announced on February 3rd, 

ZIOP had started the year trading around $5, it had been under $3 back in October of 2014.  By March of 2015 it was pushing north of $14....almost tripling from where it started the year and going up close to 500% in 6 months from October 2014 to March 2015.

What was the catalyst?  I would say it was an annoucement made at JP Morgan's Health Care conference in January that the MD Anderson Cancer Centre had "chosen" Ziopharm to partner with in developing a CAR-T cancer treatment.  That helped propel ZIOP from the $5 area where it started the year to up around the $8.75 offering price.  And after that offering taking place, with other companies like Griffin, BMO and Maxim Securities involved...it was off to the races and a PPS that got up close to $15....

The big boys had supply and Ziopharm had seemingly good news (I put chosen in quotes because the Cancer Centre received $57.5 million in shares from Ziopharm)....so the PPS was off to the races.

Could something similar be brewing with Resverlogix?  

We don't have any details to speak of, just that any offering will be the result of negotiations between the company and Bloom Burton.  

But if things play out this is the script I'm hoping to see.

1) A big announcement...any day now.  And I can't think of anything better than robust Futility SSA news.  

2) A big splash at this May 2nd B&B Conference...

3) A signficant share offering that would render the need to enter into the 3rd Eye loan agreement as moot.  

4) With shares to move a steadily increasing PPS to whet the appetites of prospective investors and existing shareholders.